Neurogene stops Batten gene therapy after FDA denies request, dealing double dose of bad news Read more 

Incyte's $750M buyout rocked by pause on key trial, asset cull Read more 

Nearing potential FDA approval, BridgeBio shows additional positive data on ATTR-CM candidate acoramidis Read more 

Pharma Sustainability Integrates 2025

Pharma Sustainability Integrates 2025 brings together top experts, leaders, and policymakers to explore strategies for reducing the pharmaceutical sector’s environmental impact. Focused on actionable solutions [...]

Go to Top